Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Using negative control outcomes and difference-in-differences to estimate treatment effects in an entirely treated cohort: the effect of ivacaftor in cystic fibrosis

Newsome, Simon J., Daniel, Rhian M., Carr, Siobhan B., Bilton, Diana and Keogh, Ruth H. 2021. Using negative control outcomes and difference-in-differences to estimate treatment effects in an entirely treated cohort: the effect of ivacaftor in cystic fibrosis. American Journal of Epidemiology 10.1093/aje/kwab263
Item availability restricted.

[img] PDF - Accepted Post-Print Version
Restricted to Repository staff only until 9 November 2022 due to copyright restrictions.

Download (953kB)

Abstract

When an entire cohort of patients receives a treatment it is difficult to estimate the treatment effect in the treated because there are no directly comparable untreated patients. Attempts can be made to find a suitable control group, (e.g. historical controls), but underlying differences between the treated and untreated can result in bias. We show how negative control outcomes (NCO) combined with difference-in-differences analysis can be used to assess bias in treatment effect estimates and obtain unbiased estimates under certain assumptions. Causal diagrams and potential outcomes are used to explain the methods and assumptions. We apply the methods to UK Cystic Fibrosis (CF) Registry data to investigate the effect of ivacaftor, introduced in 2012 for a subset of the CF population with a particular genotype, on lung function and days receiving intravenous antibiotics (IV days). We consider two NCOs: outcomes measured in the pre-ivacaftor period and outcomes in individuals ineligible for ivacaftor due to their genotype. Ivacaftor was found to improve lung function in year one (~6.5 increase in FEV1%), was associated with reduced lung function decline (~0.5 decrease in annual FEV1% decline, though confidence intervals include 0), and reduced the rate of IV days (~60% over 3 years).

Item Type: Article
Date Type: Published Online
Status: In Press
Schools: Medicine
Publisher: Bloomberg School of Public Health
ISSN: 0002-9262
Date of First Compliant Deposit: 14 October 2021
Date of Acceptance: 27 October 2021
Last Modified: 01 Dec 2021 02:22
URI: http://orca.cardiff.ac.uk/id/eprint/144846

Actions (repository staff only)

Edit Item Edit Item